[company_age]3.0[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]smartbax is a biotechnology company dedicated to developing a new generation of antibiotics to combat the growing threat of multi-drug resistant bacteria. The company's unique approach focuses on creating multi-targeted antibacterial compounds that simultaneously address multiple targets within bacteria, making it significantly more difficult for resistance to develop. This strategy stands in stark contrast to the majority of antibiotics currently in development, which are based on existing classes with well-established resistance mechanisms. \n\nsmartbax's research and development efforts are led by a team of experts with extensive experience in antibiotic discovery. The company's scientific foundation is built upon groundbreaking research conducted by Prof. Dr. Stephan Sieber's group at the Technical University of Munich, which resulted in the development of a novel class of antibiotic compounds with potent activity against Gram-positive, multi-drug resistant bacteria. This research has been recognized with prestigious awards, including the VIP+ validation prize from the German Federal Ministry of Education and Research and the m4 award from the Bavarian Ministry of Economic Affairs, Regional Development and Energy.\n\nsmartbax is committed to addressing the urgent need for new antibiotics and is actively pursuing preclinical development of its lead compounds. The company has secured €1.9 million in funding from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF) to support its research and development activities. With its innovative approach and dedicated team, smartbax is poised to make a significant contribution to the fight against antimicrobial resistance.[/description][ps]Novel multi-targeted, antibacterial compounds[/ps]